Needham analyst Gil Blum has maintained their bullish stance on ACLX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gil Blum’s rating is based on several compelling factors surrounding Arcellx Inc’s prospects. The company’s anito-cel therapy has demonstrated promising efficacy in the iMMagine-1 study, aligning with results from CARTITUDE-1, and importantly, has not shown delayed neurotoxicities even with extended follow-up periods. This favorable safety profile suggests potential for broader application in earlier lines of treatment for relapsed/refractory multiple myeloma, which could significantly expand its market reach.
Additionally, Arcellx’s strategic plans for anito-cel’s launch, including its anticipated availability in approximately 160 ATCs and a competitive vein-to-vein time of less than 17 days, position the company well to capture a substantial portion of the 4L+ multiple myeloma market. The enthusiasm from key opinion leaders about these developments further supports the positive outlook for Arcellx, underpinning Gil Blum’s Buy rating.